Quality of Life in SMA Patients Under Treatment With Nusinersen
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2021.626787
Abstract: Background: Spinal Muscular Atrophy (SMA) is a severe neurodegenerative disease, characterized by progressive muscle weakness and atrophy. The approval of the antisense oligonucleotide (ASO) nusinersen now provides an effective pharmacological approach with the potential to… read more here.
Keywords: sma patients; gqol; treatment; sma ... See more keywords